BioVaxys Technology Corp. (CNSX: BIOV)
Health Care · Pharmaceuticals · CA
CA$—
— today · — 1Y
BioVaxys Technology Corp. (CNSX: BIOV) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $2.27M and employs 3 people.
trading between 0.03 and 0.40.
Tweenvest scores BioVaxys Technology Corp. across four factors: quality 12/100. Its strongest factor is quality.
BIOV price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.27M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.22
- Dividend yield
- —
- Beta (5Y)
- 1.09
- 52-week high
- CA$0.40
- 52-week low
- CA$0.03
- Avg volume (3M)
- —
- Shares outstanding
- 44.09M
- Employees
- 3
- Next earnings
- —
About BioVaxys Technology Corp.
BioVaxys Technology Corp. is a clinical-stage biotechnology company specializing in the development of vaccine platforms designed to combat both viral infections and cancer. The company's pipeline includes BVX-0320, a single-strain vaccine for SARS-CoV-2, and BVX-0918A, an experimental haptenized tumor cell vaccine targeting ovarian cancer. Additionally, BioVaxys offers CoviDTH, an immunodiagnostic tool to detect immune system activity in SARS-CoV-2-exposed patients. Further initiatives encompass Papilocare, aimed at HPV-dependent cervical lesions, along with BVX-0918C for cervical cancer, the HPV viral vaccine BVX-0204, and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys has established strategic collaborations, such as a bioproduction agreement with WuXi Biologics Limited to manufacture SARS-CoV-2 s-proteins crucial for BVX-0320 and CoviDTH. It also holds a research partnership with The Ohio State University, Wexner School of Medicine, focusing on BVX-0320, and has engaged Bioanalytical Systems, Inc. for preclinical toxicology evaluations of its CoviDTH immunodiagnostic. The company is headquartered in Vancouver, Canada.
- ISIN
- CA09076M2004
- Listed since
- Nov 27, 2018
- Exchange
- Canadian National Stock Exchange
- Currency
- CAD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,190.78 | -3.48% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $270.49 | -0.97% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $153.60 | -1.82% |
| Roche Holding AGSWX: ROP | $371.62B | CHF368.30 | -1.47% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.34 | -1.94% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.40 | -0.60% |
Figures last refreshed Aug 18, 2026.